GRL-0617
Identifiers | |
---|---|
IUPAC name
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
ChEBI | |
ChEMBL | |
Chemical and physical data | |
Formula | C20H20N2O |
Molar mass | 304.393 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
GRL-0617 is a drug which is one of the first compounds discovered that acts as a selective small-molecule inhibitor of the protease enzyme papain-like protease (PLpro) found in some pathogenic viruses, including the coronavirus SARS-CoV-2. It has been shown to inhibit viral replication in vitro.[1][2][3][4]
See also
References
- ↑ Shin D, Mukherjee R, Grewe D, Bojkova D, Baek K, Bhattacharya A, et al. (November 2020). "Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity". Nature. 587 (7835): 657–662. Bibcode:2020Natur.587..657S. doi:10.1038/s41586-020-2601-5. PMC 7116779. PMID 32726803.
- ↑ Hajbabaie R, Harper MT, Rahman T (February 2021). "Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease" (PDF). Molecules. 26 (4): 1134. doi:10.3390/molecules26041134. PMC 7924369. PMID 33672721.
- ↑ Lim CT, Tan KW, Wu M, Ulferts R, Armstrong LA, Ozono E, et al. (July 2021). "Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp3 papain-like protease". The Biochemical Journal. 478 (13): 2517–2531. doi:10.1042/BCJ20210244. PMC 8286840. PMID 34198325.
- ↑ Xiang R, Yu Z, Wang Y, Wang L, Huo S, Li Y, et al. (July 2021). "Recent advances in developing small-molecule inhibitors against SARS-CoV-2". Acta Pharmaceutica Sinica. B. doi:10.1016/j.apsb.2021.06.016. PMC 8260826. PMID 34249607.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.